Atara Biotherapeutics has named Dietmar Berger, M.D., Ph.D., as its global head of R&D. Berger joins after seven years at Roche’s Genentech, during which time he had a hand in the approval of drugs including PD-L1 checkpoint inhibitor Tecentriq.
Denali Therapeutics, launched in May 2015 by three former Genentech researchers, just went public, raising $250 million with shares priced at $18. It is trading under the ticker DNLI.